# A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

> **NCT02732184** · PHASE2 · COMPLETED · sponsor: **Aeglea Biotherapeutics** · enrollment: 29 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Co-ArgI-PEG modified human arginase I

## Key facts

- **NCT ID:** NCT02732184
- **Lead sponsor:** Aeglea Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02732184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02732184, "A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT02732184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*